Figure 1.

Flowchart of the included study population. Two patients were excluded from the primary safety population: one patient underwent bronchoscopic (not transthoracic) Ad-CCL21-DC injection and one patient withdrew from the trial after the first cycle. The full inclusion and exclusion criteria can be found in Supplementary Table 1.